Skip to main content
Article thumbnail
Location of Repository

Losartan Decreases p42/44 MAPK Signaling and Preserves LZ+ MYPT1 Expression

By Erhan Ararat and Frank V. Brozovich


Heart failure is associated with impairment in nitric oxide (NO) mediated vasodilatation, which has been demonstrated to result from a reduction in the relative expression of the leucine zipper positive (LZ+) isoform of the myosin targeting subunit (MYPT1) of myosin light chain phosphatase. Further, captopril preserves normal LZ+ MYPT1 expression, the sensitivity to cGMP-mediated vasodilatation and modulates the expression of genes in the p42/44 MAPK and p38 MAPK signaling cascades. This study tests whether angiotensin receptor blockade (ARB) with losartan decreases p42/44 MAPK or p38 MAPK signaling and preserves LZ+ MYPT1 expression in a rat infarct model of heart failure. In aortic smooth muscle, p42/44 MAPK activation increases and LZ+ MYPT1 expression falls after LAD ligation. Losartan treatment decreases the activation of p42/44 MAPK to the uninfarcted control level and preserves normal LZ+ MYPT1 expression. The expression and activation of p38 MAPK, however, is low and does not change following LAD ligation or with losartan therapy. These data suggest that either reducing or blocking the effects of circulating angiotensin II, both decreases the activation of the p42/44 MAPK signaling cascade and preserves LZ+ MYPT1 expression. Thus, the ability of ACE-inhibitors and ARBs to modulate the vascular phenotype, to preserve normal flow mediated vasodilatation may explain the beneficial effects of these drugs compared to other forms of afterload reduction in the treatment of heart failure

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2000). A myosin phosphatase targeting subunit isoform transition defines a smooth muscle developmental phenotypic switch.
  2. (2001). A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
  3. (1987). Biochemistry of the Contractile Process in Smooth Muscle. Physiology of the Gastrointestinal Tract.
  4. (2006). Captopril prevents myosin light chain phosphatase isoform switching to preserve normal cGMPmediated vasodilatation.
  5. (2007). cGMP-dependent relaxation of smooth muscle is coupled with the change in the phosphorylation of myosin phosphatase.
  6. (2000). cGMPmediated phosphorylation of heat shock protein 20 may cause smooth muscle relaxation without myosin light chain dephosphorylation in swine carotid artery.
  7. (2007). Conditioning effect of blood flow on resistance artery smooth muscle myosin phosphatase.
  8. (2007). Cyclic GMP regulation of myosin phosphatase: A new piece for the puzzle? Circ Res
  9. (1999). Cyclic GMP-dependent protein kinase activates cloned BKCa channels expressed in mammalian cells by direct phosphorylation at serine 1072.
  10. (2000). Determinants of the contractile properties in the embryonic chicken gizzard and aorta.
  11. (2004). Dynamic changes in expression of myosin phosphatase in a model of portal hypertension.
  12. (1992). Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.
  13. (1997). Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.
  14. (1999). Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats.
  15. (2005). Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodeling.
  16. (1999). Endothelium-derived relaxing factor: Discovery, early studies, and identification as nitric oxide.
  17. (2008). Gene expression profiles of vascular smooth muscle show differential expression of mitogen-activated protein kinase pathways during captopril therapy of heart failure.
  18. Griendling KK (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system.
  19. (1987). Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure.
  20. (2008). High blood pressure arising from a defect in vascular function.
  21. (1997). Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure: role of angiotensin II.
  22. (1985). Influence of chronic captopril therapy on the infarcted left ventricle of the rat.
  23. (2005). Losartan and acute myocardial infarction in insulin-resistant Zucker fatty rats: Reduced ventricular arrhythmias and improved survival.
  24. (1992). Myosin light chain phosphatase activities and the effects of phosphatase inhibitors in tonic and phasic smooth muscle.
  25. (1998). Myosin light chain phosphatase: subunit composition, interactions and regulation.
  26. (2006). Myosin phosphatase isoform switching in vascular smooth muscle development.
  27. (2007). MYPT1 mutants demonstrate the importance of aa 888–928 for the interaction with PKGI{alpha}.
  28. (1999). Noninvasive evaluation of cardiac dysfunction by echocardiography in streptozotocininduced diabetic rats.
  29. (2006). p38 MAP kinase activity is correlated with angiotensin II type 1 receptor blocker-induced left ventricular reverse remodeling in spontaneously hypertensive heart failure rats.
  30. (2004). p38 mitogenactivated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat.
  31. (2006). PHI-1 interacts with the catalytic subunit of myosin light chain phosphatase to produce a Ca(2+) independent increase in MLC(20) phosphorylation and force in avian smooth muscle.
  32. (2001). Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway.
  33. (1999). Regulation of myosin phosphatase by a specific interaction with cGMPdependent protein kinase Ia.
  34. (2001). Role of myosin phosphatase isoforms in cGMP-mediated smooth muscle relaxation.
  35. (2001). Site-specific phosphorylation and point mutations of telokin modulate its Ca2+-desensitizing effect in smooth muscle.
  36. (2006). Smooth muscle of telokin-deficient mice exhibits increased sensitivity to Ca2+ and decreased cGMP-induced relaxation.
  37. (2004). Smooth muscle phosphatase is regulated in vivo by exclusion of phosphorylation of threonine 696 of MYPT1 by phosphorylation of Serine 695 in response to cyclic nucleotides.
  38. Somlyo AV (2003) Ca2+ sensitivity of smooth muscle and n o n m u s c l em y o s i nI I :m o d u l a t e db yGp r o t e i n s ,k i n a s e s ,a n dm y o s i n phosphatase.
  39. (1998). Somlyo AV, Somlyo AP
  40. (1998). The large conductance, voltage-dependent, and calcium-sensitive K+ channel, Hslo, is a target of cGMP-dependent protein kinase phosphorylation in vivo.
  41. (1993). The nitric oxide and cGMP signal transduction system: regulation and mechanism of action.
  42. (1980). The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.
  43. (2008). Tra2beta as a novel mediator of vascular smooth muscle diversification.
  44. (2004). Unzipping the role of myosin light chain phosphatase in smooth muscle cell relaxation.
  45. (2008). Uterine artery myosin phosphatase isoform switching and increased sensitivity to SNP in a rat L-NAME model of hypertension of pregnancy.
  46. (2004). Vascular reactivity in heart failure. Role of myosin light chain phosphatase.
  47. (2001). Zipper-interacting protein kinase induces Ca2+-free smooth muscle contraction via myosin light chain phosphorylation.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.